Document is current
Any future updates will be listed below
-
Authors
Mohyuddin, Ghulam Rehman https://orcid.org/0000-0001-6464-783X
Rubinstein, Samuel M.
Kumar, Shaji https://orcid.org/0000-0001-5392-9284
Rajkumar, S. Vincent https://orcid.org/0000-0002-5862-1833
Fonseca, Rafael https://orcid.org/0000-0002-5938-3769
Abdallah, Nadine H. https://orcid.org/0000-0001-9195-1589
Calip, Gregory S. https://orcid.org/0000-0002-7744-3518
Wang, Xiaoyan
Parrinello, Christina M.
Sborov, Douglas
- License Information
-
More Information
Article History
Received: 24 December 2023
Revised: 17 May 2024
Accepted: 29 May 2024
First Online: 11 June 2024
Competing interests
: The authors declare the following conflicts of interest: Mohyuddin: MashupMD: Royalties for writing, and institutional funding from Janssen for Dr. Mohyuddin being a site principal investigator for a Phase III trial. Rubinstein: Consulting with Janssen, Sanofi, Roche Diagnostics, and EUSA Pharma. Kumar: Consulting/advisory board participation (with no personal payments) with AbbVie, BMS, Janssen, Roche-Genentech, Takeda, Pfizer, Loxo Oncology, K36, Sanofi, ArcellX, and Beigene. Fonseca: Antegene: Membership on an entity’s Board of Directors or advisory committees; Regeneron: Consultancy; Oncotracker: Membership on an entity’s Board of Directors or advisory committees; Millenium: Consultancy; Binding Site: Consultancy; Janssen: Consultancy; Juno: Consultancy; Merck: Consultancy; Pfizer: Consultancy; Aztrazenica: Consultancy; Kite: Consultancy; Adaptive Biotechnologies: Membership on an entity’s Board of Directors or advisory committees; Sanofi: Consultancy; BMS (Celgene): Consultancy; Takeda: Consultancy; AMGEN: Consultancy; FISH: Patents & Royalties: FISH; AZBio: Membership on an entity’s Board of Directors or advisory committees; Bayer: Consultancy; Pharmacyclics: Consultancy; Caris Life Sciences: Membership on an entity’s Board of Directors or advisory committees; Adaptive Biotechnologies: Consultancy; AbbVie: Consultancy. Calip: Roche: Current equity holder in publicly-traded company. Wang: Flatiron Health: Current Employment; Roche: Current equity holder in publicly-traded company. Parrinello: Flatiron Health: Consultancy; Clue by Biowink: Consultancy; Evidation Health: Consultancy; EQRx: Consultancy; Roche: Current equity holder in publicly-traded company; Medicus Economics: Consultancy; Jazz Pharmaceuticals: Consultancy; Omada Health: Consultancy; Plinth: Consultancy; TTI Health: Consultancy; Canopy Care: Consultancy; IQ Solutions: Consultancy; Outcomes4Me: Consultancy. Sborov: Gilead: Research Funding; Arcellx: Consultancy, Research Funding; Bioline: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; BMS: Consultancy; Abbvie: Consultancy; Sanofi: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Amgen: Research Funding; GSK: Consultancy, Research Funding; Cantex: Research Funding; RocheX: Research Funding.
: This research was IRB approved by the University of Utah, as part of an agreement with Flatiron (and did not directly have any encounter with human subjects.
